Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Florence – page 8

820 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Florence at a glance
820
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

820 trials in Florence

Open in trial search

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Pericarditis

Recruiting

A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Kiniksa Pharmaceuticals GmbH

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

Polyneuropathy

Recruiting

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Florence

What the registry says about research in the country

01 Neurological Disorders

Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Seizure Control in Dravet Syndrome

Emphasis on safety assessment and long-term efficacy monitoring.

02 Oncology Research

Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Breast Cancer Therapies
  • NSCLC Post-Surgery Care

Focus on targeted therapies and personalized treatment approaches.

03 Autoimmune Conditions

Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.

  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Treatment
  • Systemic Sclerosis Interventions

Studies aim to improve quality of life and disease management.

04 Respiratory Medicine

Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.

  • COPD Exacerbation Management
  • RSV Prevention in Infants
  • Respiratory Disease Therapies

Focus on improving respiratory outcomes and prevention strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.